BCL6 and neoplasm: Together, these data (Figs 3 and 4) confirmed the screen result in identifying BCL6 as a potential paclitaxel resistance mediator (Fig. 1), which upon knockdown or inhibition results in a further cancer cell/tumor growth disadvantage in the context of paclitaxel treatment.